Amgen (AMGN) Ceases Ganitumab Phase 3 GAMMA; DMC Says Statistically Significant Improvement Unlikely
Tweet Send to a Friend
Amgen (Nasdaq: AMGN) today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
